Phase I Clinical Study of the Subunit Betulin-Adjuvanted Tetravalent Candidate Influenza Vaccine TetraFluBet
TetraFluBet tetravalent inactivated subunit vaccine with adjuvant demonstrated pronounced immunogenic properties, leading to the formation of both specific humoral and cellular immunity at a 20 μg dose.
Authors
- Dmitry A. Lioznov (ORCID: https://orcid.org/0000-0003-3643-7354)
- A. V. Ivanov (ORCID: https://orcid.org/0000-0002-7608-1914)
- T. S. Zubkova (ORCID: https://orcid.org/0000-0002-7971-5855)
- Ekaterina Romanovskaya-Romanko (ORCID: https://orcid.org/0000-0001-7560-398X)
- Irina Tcymbarevich (ORCID: https://orcid.org/0009-0000-4479-3848)
- A. A. Krasheninnikova (ORCID: https://orcid.org/0000-0002-7985-9314)
- M.M. Sukhova (ORCID: https://orcid.org/0000-0002-4572-1878)
- A. E. Mironov
- Marina Stukova (ORCID: https://orcid.org/0000-0002-2127-3820)
- I. V. Krasilnikov (ORCID: https://orcid.org/0000-0002-5048-7828)
Institutions
- R-Pharm (Russia) (RU)
- Ministry of Health of the Russian Federation (RU)
- Research Institute of Influenza (RU)
Publication Details
- Journal
- Vaccines
- Published
- 2024-09-05
- DOI
- https://doi.org/10.3390/vaccines12091017
- Primary Topic
- Pediatric health and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00